Danaher Q3 2026 Earnings Raise Full-Year Guidance
Danaher Q3 2026 earnings showed stronger demand, margin expansion and $1.6 billion free cash flow and raised full-year EPS guidance prompting repositioning
KEY TAKEAWAYS
- Danaher raised full-year adjusted diluted EPS guidance to $8.57-$8.62.
- Q3 adjusted diluted EPS was $2.11 on $6.6 billion revenue.
- Adjusted operating margin widened to about 29.0% and non-GAAP free cash flow was $1.6 billion.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Danaher reported stronger third-quarter 2026 results on Oct. 21, 2026, prompting the company to raise its full-year adjusted diluted EPS guidance. Management cited improving end-market demand, better execution, and robust cash generation as drivers of the performance.
Quarter Results and Margins
Danaher posted third-quarter revenue of $6.6 billion, an 8.5% increase year over year. Adjusted diluted EPS rose 11.5% to $2.11, while GAAP net earnings climbed 34.5% to $1.2 billion, or $1.71 per diluted share.
Non-GAAP core revenue grew 3.0% year over year, accelerating to 5.5% when excluding respiratory revenue. Management said these trends indicate improving underlying demand despite unevenness in some end markets.
Adjusted operating margin expanded 110 basis points to about 29.0%, driven mainly by operational execution and a modest benefit from tariff refunds. Operating cash flow reached $1.9 billion, with non-GAAP free cash flow at $1.6 billion for the quarter. Year-to-date free cash flow totaled approximately $4.0 billion.
Guidance and Demand Outlook
Danaher raised its full-year 2026 adjusted diluted EPS guidance to a range of $8.57 to $8.62 from $8.45 to $8.60, reflecting the stronger third quarter and improved margins and cash flow.
For the fourth quarter, management expects core revenue excluding respiratory to grow about 4.0% to 5.0% year over year. Respiratory revenue will reduce total core revenue growth by roughly 150 basis points, resulting in an estimated 3.0% increase. Adjusted operating margin for the quarter is forecast near 29.5%. The respiratory impact is described as a temporary sector pressure amid an otherwise improving environment.
Executives reported mid-single-digit or better core revenue growth excluding respiratory in biotechnology, life sciences, and diagnostics. Demand from large pharmaceutical and biopharmaceutical customers strengthened, academic demand improved but remained below historical levels, and clinical and applied markets were healthy. Management outlined an initial 2027 framework targeting about 4.0% to 5.0% core revenue growth excluding respiratory, with more detailed guidance planned for January.
